CTLA4 and melanoma: We also found 99 patients who received anti‐CTLA4 treatment, including 75 patients with melanoma (43 with TERT mutations and 32 with TERT wild type), 20 patients with breast cancer (all with TERT wild type), and four patients with other cancer types (also TERT wild type).